Historical Valuation
Cartesian Therapeutics Inc (RNAC) is now in the Fair zone, suggesting that its current forward PS ratio of 369.92 is considered Fairly compared with the five-year average of -5.55. The fair price of Cartesian Therapeutics Inc (RNAC) is between 2.55 to 9.87 according to relative valuation methord.
Relative Value
Fair Zone
2.55-9.87
Current Price：8.12
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Cartesian Therapeutics Inc (RNAC) has a current Price-to-Book (P/B) ratio of -4.90. Compared to its 3-year average P/B ratio of 78.73 , the current P/B ratio is approximately -106.23% higher. Relative to its 5-year average P/B ratio of 78.73, the current P/B ratio is about -106.23% higher. Cartesian Therapeutics Inc (RNAC) has a Forward Free Cash Flow (FCF) yield of approximately -39.19%. Compared to its 3-year average FCF yield of -20.41%, the current FCF yield is approximately 92.07% lower. Relative to its 5-year average FCF yield of -20.41% , the current FCF yield is about 92.07% lower.
P/B
Median3y
78.73
Median5y
78.73
FCF Yield
Median3y
-20.41
Median5y
-20.41
Competitors Valuation Multiple
AI Analysis for RNAC
The average P/S ratio for RNAC competitors is 137.86, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC.O) exhibits a P/S ratio of 369.92, which is 168.33% above the industry average. Given its robust revenue growth of 16.80%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RNAC
1Y
3Y
5Y
Market capitalization of RNAC increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RNAC in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RNAC currently overvalued or undervalued?
Cartesian Therapeutics Inc (RNAC) is now in the Fair zone, suggesting that its current forward PS ratio of 369.92 is considered Fairly compared with the five-year average of -5.55. The fair price of Cartesian Therapeutics Inc (RNAC) is between 2.55 to 9.87 according to relative valuation methord.
What is Cartesian Therapeutics Inc (RNAC) fair value?
RNAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cartesian Therapeutics Inc (RNAC) is between 2.55 to 9.87 according to relative valuation methord.
How does RNAC's valuation metrics compare to the industry average?
The average P/S ratio for RNAC's competitors is 137.86, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC) exhibits a P/S ratio of 369.92, which is 168.33% above the industry average. Given its robust revenue growth of 16.80%, this premium appears unsustainable.
What is the current P/B ratio for Cartesian Therapeutics Inc (RNAC) as of Jan 10 2026?
As of Jan 10 2026, Cartesian Therapeutics Inc (RNAC) has a P/B ratio of -4.90. This indicates that the market values RNAC at -4.90 times its book value.
What is the current FCF Yield for Cartesian Therapeutics Inc (RNAC) as of Jan 10 2026?
As of Jan 10 2026, Cartesian Therapeutics Inc (RNAC) has a FCF Yield of -39.19%. This means that for every dollar of Cartesian Therapeutics Inc’s market capitalization, the company generates -39.19 cents in free cash flow.
What is the current Forward P/E ratio for Cartesian Therapeutics Inc (RNAC) as of Jan 10 2026?
As of Jan 10 2026, Cartesian Therapeutics Inc (RNAC) has a Forward P/E ratio of -1.99. This means the market is willing to pay $-1.99 for every dollar of Cartesian Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cartesian Therapeutics Inc (RNAC) as of Jan 10 2026?
As of Jan 10 2026, Cartesian Therapeutics Inc (RNAC) has a Forward P/S ratio of 369.92. This means the market is valuing RNAC at $369.92 for every dollar of expected revenue over the next 12 months.